|
1
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase-AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002.
|
|
2
|
Bader AG, Kang S, Zhao L and Vogt PK:
Oncogenic PI3K deregulates transcriptionand translation. Nat Rev
Cancer. 5:921–929. 2005.
|
|
3
|
Wang SI, Puc J, Li J, et al: Somatic
mutations of PTEN in glioblastoma multiforme. Cancer Res.
57:4183–4186. 1997.
|
|
4
|
Sun M, Paciga JE, Feldman RI, et al:
Phosphatidylinositol-3-OH-Kinase (PI3K)/AKT2, activated in breast
cancer, regulates and is induced by estrogen receptor alpha
(ERalpha) via interaction between ERalpha and PI3K. Cancer Res.
61:5985–5991. 2001.
|
|
5
|
Shayesteh L, Lu Y, Kuo WL, et al: PIK3CA
is implicated as an oncogene in ovarian cancer. Nat Genet.
21:99–102. 1999.
|
|
6
|
Yokoyama Y, Wan X, Shinohara A, et al:
Expression of PTEN and PTEN pseudogene in endometrial carcinoma.
Int J Mol Med. 6:47–50. 2000.
|
|
7
|
Forgacs E, Biesterveld EJ, Sekido Y, et
al: Mutation analysis of the PTEN/MMAC1 gene in lung cancer.
Oncogene. 17:1557–1565. 1998.
|
|
8
|
Dahia PL, Marsh DJ, Zheng Z, et al:
Somatic deletions and mutations in the Cowden disease gene, PTEN,
in sporadic thyroid tumors. Cancer Res. 57:4710–4713. 1997.
|
|
9
|
Jaiswal BS, Janakiraman V, Kljavin NM, et
al: Somatic mutations in p85alpha promote tumorigenesis through
class IA PI3K activation. Cancer Cell. 16:463–474. 2009.
|
|
10
|
Sun M, Hillmann P, Hofmann BT, Hart JR and
Vogt PK: Cancer-derived mutations in the regulatory subunit
p85alpha of phosphoinositide 3-kinase function through the
catalytic subunit p110alpha. Proc Natl Acad Sci USA.
107:15547–15552. 2010.
|
|
11
|
Cortés I, Sánchez-Ruíz J, Zuluaga S, et
al: p85β phosphoinositide 3-kinase subunit regulates tumor
progression. Proc Natl Acad Sci USA. 109:11318–11823. 2012.
|
|
12
|
Taniguchi CM, Winnay J, Kondo T, et al:
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert
tumor suppressor properties through negative regulation of growth
factor signaling. Cancer Res. 70:5305–5315. 2010.
|
|
13
|
Folgiero V, Di Carlo SE, Bon G, et al:
Inhibition of p85, the non-catalytic subunit of
phosphatidylinositol 3-kinase, exerts potent antitumor activity in
human breast cancer cells. Cell Death Dis. 3:e4402012.
|
|
14
|
Camp RL, Dolled-Filhart M and Rimm DL:
X-tile: a new bio-informatics tool for biomarker assessment and
outcome-based cut-point optimization. Clin Cancer Res.
10:7252–7259. 2004.
|
|
15
|
Miller TW, Rexer BN, Garrett JT and
Arteaga CL: Mutations in the phosphatidylinositol 3-kinase pathway:
role in tumor progression and therapeutic implications in breast
cancer. Breast Cancer Res. 13:2242011.
|
|
16
|
NCCN clinical practice guidelines in
breast cancer. 2013, version 2 http://www.nccn.org/.
Accessed May 1 2013
|
|
17
|
Lin X, Böhle AS, Dohrmann P, et al:
Overexpression of phosphatidylinositol 3-kinase in human lung
cancer. Langenbecks Arch Surg. 386:293–301. 2001.
|
|
18
|
Sorlie T, Tibshirani R, Parker J, et al:
Repeated observation of breast tumor subtypes in independent gene
expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003.
|
|
19
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948.
2010.
|
|
20
|
Zito CR, Jilaveanu LB, Anagnostou V, et
al: Multi-level targeting of the phosphatidylinositol-3-kinase
pathway in non-small cell lung cancer cells. PLoS One.
7:e313312012.
|
